Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients

Inclusion Criteria: All patients: * Histologically-confirmed advanced solid tumors * Progressive, recurrent unresectable disease * World Health Organization (WHO) Performance status ≤ 2 * No history of primary brain tumor or brain metastases MTD Expansion part: * Histologically-confirmed advanced solid tumors * Progressive, recurrent unresectable disease * World Health Organization (WHO) Performance status ≤ 2 * No history of primary brain tumor; no brain metastases unless asymptomatic and clinically stable for ≥ 3 months * Patients with genetic or molecular alteration of the PI3K pathway Exclusion Criteria: * Prior treatment with a PI3K inhibitor * History of or active major depressive episode, bipolar disorder, schizophrenia, or history of suicidal attempt or ideation * No clinically manifest diabetes mellitus (treated and/or with clinical signs) * No acute or chronic renal disease * No acute or chronic liver disease * No acute or chronic pancreatitis * No unresolved diarrhea * No impaired cardiac function or clinically significant cardiac diseases such as ventricular arrhythmia, congestive heart failure, uncontrolled hypertension * No acute myocardial infarction or unstable angina pectoris within the past 3 months * Not pregnant or nursing and fertile patients must use barrier contraceptives Other protocol-defined inclusion/exclusion criteria may apply